Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Company research

Medicus Sciences Acquisition Corp.

CIK 1836517Updated Sep 24, 2026

MSAC price & chart

Provider market data
Historical security

This listing closed Feb 17, 2023. Live provider charts are shown only for current listings.

In the news

No coverage from other publishers is available.

Recent filings

  1. SC 13G/A filing

    SC 13G/A · 2024-02-12 · 0001604488-24-000047

  2. SC 13G/A filing

    SC 13G/A · 2024-02-08 · 0001062993-24-002516

  3. 15-12G filing

    15-12G · 2023-02-27 · 0001104659-23-025886

  4. 25-NSE filing

    25-NSE · 2023-02-17 · 0001354457-23-000099

  5. SC 13G/A filing

    SC 13G/A · 2023-02-14 · 0001104659-23-021733

Show 5 more recent filings
  1. SC 13G filing

    SC 13G · 2023-02-14 · 0001604488-23-000043

  2. 8-K filing

    8-K · 2023-02-13 · 0001104659-23-018919

  3. SC 13G/A filing

    SC 13G/A · 2023-02-10 · 0000899140-23-000273

  4. SC 13G/A filing

    SC 13G/A · 2023-01-24 · 0001085146-23-000337

  5. 8-K filing

    8-K · 2023-01-18 · 0001104659-23-004407

Financials

FY 2021 · USD
Revenue · FY 2021
Net income1,897,877USD · FY 2021
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Operating income-614,675USD · FY 2021
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Diluted EPS · FY 2021

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemFY 2021FY 2020
ASSETS
AssetsUSD93,624,429
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2021-12-31

129,186
Source

10-Q · 2021-05-24 · 0001104659-21-070794

As of 2020-12-31

Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD1,433,753
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2021-12-31

2,000
Source

10-Q · 2021-05-24 · 0001104659-21-070794

As of 2020-12-31

Assets, CurrentUSD1,580,004
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2021-12-31

2,000
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2020-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD8,267,336
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2021-12-31

110,254
Source

10-Q · 2021-05-24 · 0001104659-21-070794

As of 2020-12-31

Stockholders’ equity:
Additional Paid in CapitalUSD24,768
Source

10-Q · 2021-05-24 · 0001104659-21-070794

As of 2020-12-31

Retained Earnings (Accumulated Deficit)USD-6,643,148
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2021-12-31

-6,068
Source

10-Q · 2021-05-24 · 0001104659-21-070794

As of 2020-12-31

Stockholders' Equity Attributable to ParentUSD-6,642,907
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2021-12-31

18,932
Source

10-Q · 2021-05-24 · 0001104659-21-070794

As of 2020-12-31

Liabilities and EquityUSD93,624,429
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2021-12-31

129,186
Source

10-Q · 2021-05-24 · 0001104659-21-070794

As of 2020-12-31

Current liabilities:
Liabilities, CurrentUSD32,008
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2021-12-31

110,254
Source

10-Q · 2021-05-24 · 0001104659-21-070794

As of 2020-12-31

Additional Financial Items
Accrued Liabilities, CurrentUSD32,008
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2021-12-31

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemFY 2021FY 2020
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD1,897,877
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD-798,519
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD-92,000,000
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Cash flows from financing activities:
Net Cash Provided by (Used in) Financing ActivitiesUSD94,230,272
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD1,431,753
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD1,433,753
Source

10-K · 2022-03-31 · 0001104659-22-040275

As of 2021-12-31

2,000
Source

10-Q · 2021-05-24 · 0001104659-21-070794

As of 2020-12-31

Additional Financial Items
Investment Income, InterestUSD8,585
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Net Income (Loss) Attributable to ParentUSD1,897,877
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Nonoperating Income (Expense)USD2,512,552
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Operating Costs and ExpensesUSD614,675
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2021
Operating Income (Loss)USD-614,675
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Net Income (Loss) Attributable to ParentUSD1,897,877
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Additional Financial Items
Investment Income, InterestUSD8,585
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Nonoperating Income (Expense)USD2,512,552
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Operating Costs and ExpensesUSD614,675
Source

10-K · 2022-03-31 · 0001104659-22-040275

2021-01-01 to 2021-12-31

Lines labelled “Derived” are calculated from reported figures.